Q. What is the status of sale of Ranitidine tablet/ injection in India
Ranitidine is a schedule H drug available in the market in the form of tablet and injections.
Govt. of India has not banned under section 26 A of the Drugs and Cosmetics Act.
As per the news from FDA, USA on dated 13 September 2019 that Ranitidine formulation contains NDMA which is an impurity cause cancer.
So, Ranitidine manufacturer / formulators should get their products tested for the presence of impurities i.e. NDMA.
For more FAQs Click here